Introduction
============

*Corynebacterium diphtheriae* belong to the class Actinomycetales and is a Gram-positive bacterium, a non-spore forming, non-motile and facultative anaerobe with pleomorphic cell shape and high GC content (∼53%) relative to the *Firmicutes* ([@B13]; [@B44]). This bacterium is the causative agent of diphtheria, a severe human respiratory manifestation characterized by bacterial adhesion to host pharyngeal cell (pharyngitis and pseudomembranous inflammation). The pathogen target one or both tonsils that further disseminate at a later stage thereby resulting in complete airway obstruction and death ([@B20]). The cornerstone in diphtheria therapy involves the hyper immune antiserum-antitoxin produced in equines that neutralizes the *C. diphtheriae* toxin while among antibiotics are the broad-spectrum penicillin or erythromycin. However, recent emergence of numerous drug-resistant strains subsequently decreases the efficacy of current therapeutics ([@B7]). Importantly, the World Health Organization recommends widespread DTPs immunization against toxigenic diphtheria strains as the only effective approach to counteract the infection. Although, a slight change in mortality has been observed since the availability and administration of antibiotics, specifically penicillin or erythromycin ([@B1]). *C. diphtheriae* has four biotypes: gravis, mitis, intermedius and belfanti that are non-sporulating, unencapsulated, non-motile and pleomorphic bacilli. They are subsequently classified on the basis of differences in colonial morphology, haemolytic potential, fermentation reactions and severity of the resulting disease ([@B19]; [@B12]). The infant mortality rate in an epidemic that resulted in thousands of casualties dropped gradually in countries where living standards were improved and immunization programs were introduced. Nevertheless, it still remains a significant pathogen around the globe ([@B23]). The 'strangling angel' effects on children that scaled from wing-shaped disarticulation and pseudo-membranes formation in the oropharynx, triggered acute obstruction of airways and resulted in mortalities ([@B23]; [@B21]; [@B26]). A plethora of cases were recently reported and still expected from both non-lethal and lethal diphtheria in different parts of the world due to significant population displacements via immigration. An adequate supervision necessitates quick measures to discover additional diphtheria antitoxin, antibiotic and therapeutic treatment ([@B35]).

The emerging concepts of polypharmacology, differential genome analyses, and reverse vaccinology, comparative and subtractive microbial genomics have largely contributed by establishing complementary traditions for fast identification of novel targets in post-genomic era ([@B34]; [@B4]). Comparative homology modeling ([@B8]; [@B39]) has widely been used in expanding the structural space of pathogens ([@B14]; [@B3]).

These practices are being used for the identification of conserved targets in a several human and animal pathogens like *C. tuberculosis* ([@B22]; [@B37]), *Mycobacterium. tuberculosis* ([@B3]), *Burkholderia pseudomallei* ([@B14]), *Neisseria gonorrhoea* ([@B6]), *Helicobacter pylori* ([@B16]), *Pseudomonas aeruginosa* ([@B40]; [@B34]), and *Salmonella typhi* ([@B38]).

In this work, a combination of *in silico* tools was primarily used to predict the core proteome of *C. diphtheriae* species to associate genomic information based on the 3D structures. The predicted proteomes were modeled (pan-modelome) using a methodology adapted by [@B22]. From a structural point of view, druggability is the probability of small drug-like molecules binding to a given target protein with high affinity (\<1 μM). We report for the first time the structural druggability assessment for multi-strain *C. diphtheriae* proteomes using a pan-druggability prediction pipeline based on the open source pocket detection code "fpocket". The method integrates several physicochemical descriptors to estimate the pocket druggability on a genomic scale with suitable features that enable binding of a drug-like compound ([@B29]).

Materials and Methods {#s1}
=====================

Initial Dataset Construction
----------------------------

All ORFs (Open Reading Frames) of the 13 completely sequenced genomes of *C. diphtheriae* were obtained from the NCBI database^[1](#fn01){ref-type="fn"}^. **Table [1](#T1){ref-type="table"}** shows the statistical data of all strains used in this study where the strain NCTC13129 has 2,272 reported ORFs and was randomly selected as a reference genome for modelome prediction and further analyses.

###### 

Summary of *Corynebacterium diphtheriae* strains used in this study and their respective modeling statistics for druggability analyses.

  Strain      Biovar     Location         NCBI accession   Genome size (Mb)   GC%     Proteins   Models -- G2
  ----------- ---------- ---------------- ---------------- ------------------ ------- ---------- --------------
  31A         N/A        Brazil           NC_016799.1      2.53535            53.60   2380       1283
  241         N/A        Brazil           NC_016782.1      2.42655            53.40   2245       1235
  BH8         N/A        Brazil           NC_016800.1      2.48552            53.60   2361       1269
  C7          N/A        United States    NC_016801.1      2.49919            53.50   2337       1278
  CDCE8392    Mitis      United States    NC_016785.1      2.43333            53.60   2249       1253
  HC01        Mitis      Brazil           NC_016786.1      2.42715            53.40   2247       1236
  HC02        Mitis      Brazil           NC_016802.1      2.46861            53.70   2230       1254
  HC03        Mitis      Brazil           NC_016787.1      2.47836            53.50   2262       1260
  HC04        Gravis     Brazil           NC_016788.1      2.48433            53.50   2275       1260
  INCA402     Belfanti   Brazil           NC_016783.1      2.44907            53.70   2214       1282
  PW8         N/A        United States    NC_016789.1      2.53068            53.50   2414       1272
  VA01        Gravis     Brazil           NC_016790.1      2.39544            53.40   2191       1239
  NCTC13129   Gravis     United Kingdom   NC_002935.2      2.48863            53.50   2272       1253

General Concept: Modelome Prediction
------------------------------------

The binding affinity of small drug-like molecules to the active site of putative biological targets (druggable protein cavities) formulated a basis for this work, a slightly modified protocol of [@B37] (**Figure [1](#F1){ref-type="fig"}**). All genome ORF sequences of the 13 *C. diphtheriae* strains were subjected to the MHOLline workflow^[2](#fn02){ref-type="fn"}^ in.faa file format for 3D structure prediction. MHOLline utilizes multi fasta files of amino acids as an input data and then uses HMMTOP, BLAST, BATS, Modeller and Procheck programs for the detailed analyses. The program HMMTOP detects transmembrane regions. The BLAST algorithm is used to identify template structure by performing a random search against the Protein Data Bank. BATS (Blast Automatic Targeting for Structures) carry out the refinement in the template search; it is a key step for the model construction. BATS refinement identifies sequences that make the modeling possible by selecting a template from BLAST output file using their BATS scores, expectation values, identity and sequence similarity as criteria as well as considering the number of gaps and the alignment coverage. BATS select the best template for 3D model generation and perform automated alignment used by the MODELLER program. Furthermore, it gathers all the BLAST output files into four distinctive groups, i.e., G0, G1, G2, and G3, according to the following criteria; G0 = Not aligned sequence, G1 = *E*-value \> 10e^-5^ or Identity \< 15%, G2 = *E*-value ≤ 10e^-5^ and Identity ≥ 25% AND LVI ≤ 0.7, G3 = *E*-value ≤ 10e^-5^ and Identity ≤ 15% and \<25% OR LVI \> 0.7, Where LVI is the Length Variation Index, a MHOLline concept of coverage (LVI ≤ 0.1 is equivalent to a coverage ≥ 90%). Once the template is selected based on BATS results, MODELLER program is used for the generation of 3D protein model. There is no significant correlation statistically, between the number of templates used during model building and the overall quality of a model. In the next step, another MHOLline tool called FILTERS, categorizes the BATS selected sequences (G2) into distinct quality model subgroups, based on identity and LVI value. The subgroups ranges Very High to Very Low. To evaluate the overall quality and accuracy of the model, Ramachandran plot is obtained which explained the stereochemical quality of the model. Precisely, the MHOLine generates an aggregate structural information for all the submitted sequences in the fasta format, Ramachandran plot and other properties like structural quality and enzymatic functions are also determined. Further details can be obtained by visiting MHOLline homepage ([@B22]; [@B46]; [@B25]). For all modeled structures, structural properties were figured as: (i) the Druggability Score (DS) for each pocket and (ii) the active site residues (if available) according to the template structures available at the protein databank RCSB-PDB^[3](#fn03){ref-type="fn"}^ ([@B11]).

![Overview of pipeline components for data analysis.](fgene-09-00044-g001){#F1}

3D Protein Models in Non-reference Strains: Orthologs Identification
--------------------------------------------------------------------

We used an applied bioinformatics procedure to find the conserved putative druggable targets across all the 13 *C. diphtheriae* strains at genome-scale by first predicting their 3D models. The ensemble methodology essentially is a filter of thousands of candidate genes to yield high-confidence 3D structural models from orthologous proteins in *C. diphtheriae* species. As aforementioned, the MHOLline resulted in 1,253 predicted structures for the randomly selected reference strain NCTC13129 that were later used as template structures for modeling the 3D structures in non-reference strains as well. Further, the BLASTp program was installed in a local machine and used to check if the ORFs of the reference proteome have orthologs in the remaining 12 strains using the following parameters; identity ≥ 85%, coverage \> 80%. The protein sequences showing high identity values (\> = 85%) for each reference and non-reference strain were considered as conserved and the modeled structures of reference strain were used again as templates to predict the 3D models for the aforementioned 12 non-reference strains. The core modelome was compared and evaluated for the quality of the obtained 3D structures. A reliable model has a probability of correct fold larger than 95% and coverage of over 50% with the template structure. For each sequence in the reference and non-reference strain that gave an identity hit of \>85%, a mutation methodology was applied on each amino acid substitution using the MODELLER program. These models were then used to compute the druggability variation for the 13 strains of the *C. diphtheriae* species.

Evaluation of Structural Druggability
-------------------------------------

The protein structural druggability of each predicted 3D model was evaluated by determining the ability of putative pockets to bind drug-like molecule/s, using the fpocket ([@B17]) and the recently developed DrugScore (DS) programs ([@B45]). The later methodology is based on the Voronoi tessellation algorithm that identify and characterize pockets and compute suitable physicochemical descriptors such as polar and apolar surface area, hydrophobic-hydrophobic density and polarity score. In conjunction they yield a druggability value that ranges between 0 (non-druggable, ND) and 1 (highly druggable, HD). We categorized the druggability scores for all predicted 3D structures into four sets: non-druggable (ND; DS ≤ 0.2), poorly druggable (PD; DS ≥ 0.2 and ≤0.5), druggable (D; DS ≥ 0.5 and ≤0.7), and highly druggable (HD; DS ≥ 0.7) protein pockets, respectively. This distribution is in accordance to our previous work where the druggability score was computed for all pockets present in all unique proteins in the Protein Data Bank that were experimentally crystallized in complex with a drug-like compound/s ([@B36]).

Identification of Active Site Residues
--------------------------------------

In order to identify the amino acid residues in the active site of the predicted druggable protein pocket/s, information were retrieved from the CSA database (Catalytic Site Atlas) ([@B18]) and Pfam position site ([@B17]), respectively. A list of PDB_IDs was generated linked to a number of residues constituting the corresponding protein active sites. To map the active site residues to as many *C. diphtheriae* proteins as possible, each PDB_ID was used as a template in CSA and assigned to the modeled ORFs.

Host Homology, Essentiality, and Core-Modelomics of the Selected Targets
------------------------------------------------------------------------

For off target prediction, the pool of global druggable (GD) proteins was piped into NCBI-BLASTp using default parameters (identity = 0% and/or no hit) against the human proteome to identify non-host homologs. Moreover, from the filtered list of 10 highly druggable non-host homologous target proteins, an approach based on subtractive genomics was implemented and applied to the GD targets that were essential to bacteria ([@B5]). Briefly, the set of target proteins of *C. diphtheriae* was submitted to the Database of Essential Genes (DEG, which contains experimentally validated essential genes from bacteria, archaea and eukaryotes) for homology analyses ([@B51]). Again, we used BLASTp with *E-*value cut-off of 1e^-05^ a *bit score* ≥ 100 and *identity* ≥ 35% ([@B5]). The final list of putative targets based on criteria described earlier, contained 10 essential and non-host homologous target proteins. The obtained list was further subjected to ProtParam^[4](#fn04){ref-type="fn"}^ for molecular weight determination, biochemical pathway analysis to KEGG (Kyoto Encyclopedia of Genes and Genomes) ([@B28]) using network enrichment ([@B2]), virulence using PAIDB (Pathogenicity Island Database) ([@B49]), functionality using UniProt (Universal Protein Resource) ([@B30]), and cellular localization using CELLO (subCELlular LOcalization predictor) ([@B50]). In addition, we merged the final set of 10 selected non-host homologous, essential and global druggable proteins with results obtained through experiments locally performed in our laboratories (Jamal et al., unpublished data) resulting in three common targets, which we selected as candidates.

Protein--Protein Interaction Network
------------------------------------

In biological systems, proteins work in a homogenous environment rather than individual, hence it is important to study protein--protein interactions (PPIs) for *C. diphtheriae* metabolism. The identified drug targets were evaluated to study their potential biological, functional and metabolic roles for proteomic interactions. The selected drug targets were used to develop intra-species protein--protein interactome using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database ([@B43]). STRING is an online network analyses tool that provides essential information regarding interactions of the desired proteins.

Results and Discussion
======================

Prediction of Structural Homology Based Models
----------------------------------------------

The complete modelome of the reference strain NCTC13129 was computed; consisting of 13,763 ORF, with 1,253 (∼9%) resulting models. Taking the original models of reference strain NCTC13129 as templates, we then generated 438 conserved models in the 12 remaining strains using the MODELLER software ([@B41]). Afterward, the target-template alignments have been computed using a BLAST *E-*value cut-off of 10^-6^ in order to build the model structures using the MODELLER software ([@B41]; [@B46]). For each target-template alignment, ten different target models were built, and their quality measures have been assessed using GA341 ([@B31]; [@B32]) and QMEAN ([@B10]), keeping models with GA341 reliability scores ≥ 0.7 ([@B33]), leading to a final set of 401 protein models. All these proteins are tabulated in **Supplementary Table [S1](#SM2){ref-type="supplementary-material"}**.

Pocketome Druggability and Active Site Residues of *C. diphtheriae*
-------------------------------------------------------------------

The list of 401 targets protein drastically reduced to 137 after druggability analyses using the aforementioned fpocket and the recently developed DS programs. A summary of only highly druggable (HD) targets with drug score remained ≥ 0.7 were considered as global druggable. The calculated structural druggability scores are given in **Supplementary Table [S2](#SM3){ref-type="supplementary-material"}**.

In **Figure [2](#F2){ref-type="fig"}**, a comparison of calculated druggability score distribution across all structures of *C. diphtheriae* reference and other strains is shown. Although the distribution has a small shift to higher values, we used the same bounds to define the sets of druggable proteins (**Figure [2](#F2){ref-type="fig"}**). A protein target, which remained druggable in all strains, was classified as Globally Druggable (GD).

![Histogram of druggability score along the *Corynebacterium diphtheriae* reference/other strains. Representation of all ligand-bound structures in the PDB (blue pointed line), all modeled structures of *C. diphtheriae* reference strain (red line, 1,253 models), and all modeled structures of the *C. diphtheriae* non-reference genome strains (green line, 401 core proteins in 12 non-reference strains).](fgene-09-00044-g002){#F2}

Non-host Homology, Essentiality and Core-Modelomics Analyses
------------------------------------------------------------

As aforementioned, the list of 137 global druggable proteins (**Supplementary Table [S2](#SM3){ref-type="supplementary-material"}**) was computed to the corresponding human host proteome that resulted in the identification of a very small set of only 10 non-host homologous proteins; remaining 127 as host-homologous. The non-host homologous targets were selected following a very stringent criterion, i.e., no identity, no hits. This list of final 10 essential and non-host homologous targets in *C. diphtheriae* is given in **Table [2](#T2){ref-type="table"}**. We further report the involvement of these putative targets in metabolic pathways, biological processes, cellular localization, molecular weights and most importantly their potential role as virulence factors. Out of 10 targets, 7 targets were found as pathogen virulence factors using the PAIDB database based on homology method. Further, we predicted the subcellular localization of these final target proteins using support vector machines, a methodology that is based on n-peptide composition of proteins, adapted in a related work by [@B50], we obtained three high-confidential candidates, which are; hisE, glpX, and rpsH. Interestingly, these three high-confidential candidates were identified as essential and non-host homologous targets in our previous work by [@B25]. These proteins were subjected to molecular docking analysis against four different ligand libraries and a set of some potent molecules were suggested for active inhibition of these proteins ([@B25]).

###### 

List of global druggable, non-host homologous and essential putative targets, their functional annotation together with other information.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  S. No   Gene/protein codes     Official full name                       Mol. Wt^a^ (KDa)   Functions^b^                                                                                                                        Cell locality^c^           Pathways^d^                                                                     Virulence^e^
  ------- ---------------------- ---------------------------------------- ------------------ ----------------------------------------------------------------------------------------------------------------------------------- -------------------------- ------------------------------------------------------------------------------- --------------
  1       NP_939496.1 coaD       Phosphopantetheine adenylyltransferase   17.305             **MF:** ATP binding, pantetheine-phosphate adenylyltransferase activity.\                                                           Cytoplasm                  Pantothenate and CoA biosynthesis, metabolic pathways                           Yes
                                                                                             **BP:** coenzyme A biosynthetic process.                                                                                                                                                                                                       

  **2**   NP_939612.1 **hisE**   Phosphoribosyl-ATP pyrophosphatase       9.877              **MF:** RNA binding, phosphoribosyl-ATP diphosphatase activity.\                                                                    Cytoplasm                  Biosynthesis of amino acids                                                     Yes
                                                                                             **BP:** histidine biosynthetic process                                                                                                                                                                                                         

  3       NP_938944.1 DIP0568    Alanine racemase                         41.235             **MF:** Catalyzes the interconversion of [L]{.smallcaps}-alanine and [D]{.smallcaps}-alanine. May also act on other amino acids.\   Cytoplasm                  [D]{.smallcaps}-Alanine metabolism, Metabolic pathways, Vancomycin resistance   Yes
                                                                                             **BP:** [D]{.smallcaps}-alanine biosynthetic process                                                                                                                                                                                           

  4       NP_939875.1 rimM       16S rRNA-processing protein RimM         18.067             **MF:** ribosome binding.\                                                                                                          Cytoplasm                  Ribosome biogenesis                                                             No
                                                                                             **BP:** ribosomal small subunit biogenesis, rRNA processing                                                                                                                                                                                    

  **5**   NP_939302.1 **glpX**   Fructose 1,6-bisphosphatase II           35.589             **MF:** fructose 1,6-bisphosphate 1-phosphatase activity, metal ion binding.\                                                       Cytoplasm                  Carbohydrate metabolism                                                         No
                                                                                             **BP:** gluconeogenesis, glycerol metabolic process                                                                                                                                                                                            

  6       NP_940458.1 dcd        Deoxycytidine triphosphate deaminase     20.494             **MF:** dCTP deaminase activity.\                                                                                                   Cytoplasm                  Metabolism                                                                      Yes
                                                                                             **BP:** dUMP biosynthetic process, dUTP biosynthetic process, pyrimidine ribonucleotide biosynthetic process                                                                                                                                   

  **7**   NP_938900.1 **rpsH**   30S ribosomal protein S8                 14.292             **MF:** rRNA binding, structural constituent of ribosome.\                                                                          Extracellular/ Cytoplasm   Unknown                                                                         No
                                                                                             **BP:** translation                                                                                                                                                                                                                            

  8       NP_938817.1 rplJ       50S ribosomal protein L10                17.946             **MF:** large ribosomal subunit rRNA binding, structural constituent of ribosome.\                                                  Cytoplasm                  Genetic information processing, translation                                     Yes
                                                                                             **BP:** ribosome biogenesis, translation                                                                                                                                                                                                       

  9       NP_940678.1 rsmG       16S rRNA methyltransferase GidB          24.425             **MF:** rRNA (guanine-N7-)-methyltransferase activity.\                                                                             Cytoplasm                  Methyltransferases                                                              Yes
                                                                                             **BP:** rRNA processing                                                                                                                                                                                                                        

  10      NP_938439.1 thiE       Thiamine-phosphate synthase              23.441             **MF:** magnesium ion binding, thiamine-phosphate diphosphorylase activity.\                                                        Cytoplasm                  Thiamine metabolism, metabolic pathways                                         Yes
                                                                                             **BP:** thiamine biosynthetic process, thiamine diphosphate biosynthetic process                                                                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The underlined are the three high-confidence targets (see text).

a

Molecular weight via ProtParam tool (

http://web.expasy.org/protparam/

).

b

Molecular function (MF) and biological process (BP) for each target protein via UniProt.

c

Cellular localization of pathogen targets via CELLO.

d

KEGG for finding the role of these targets in different cellular pathways.

e

PAIDB for analyzing if the putative targets are involved in the pathogen's virulence.

### hisE (Phosphoribosyl-ATP Pyrophosphatase)

hisE is the second enzyme in histidine-biosynthetic pathway hydrolysing irreversibly phosphoribosyl-ATP to phosphoribosyl-AMP and pyrophosphate. The protein is encoded by the *hisE* gene, fused to *hisI* in many bacteria, fungi and plants but is present as a separate gene in some bacteria and archaea. Since it is seen in *in vitro* experiments that *hisE* is essential for microorganism growth, we assume it a potential drug target in *C. diphtheriae.* It is also reported as a drug candidate for tuberculosis ([@B27]).

### glpX (Fructose 1,6-Bisphosphatase II)

It is one of the main enzyme for gluconeogenesis that catalyses the hydrolysis of fructose 1,6-bisphosphate to form fructose 6-phosphate and orthophosphate. In glycolysis, phosphofructokinase catalysis the reverse reaction, and the product, fructose 6-phosphate, are important precursors in various biosynthetic pathways ([@B24]). Gluconeogenesis is an important metabolic pathway in all organisms and plays a key role by allowing the cells to synthesize glucose from non-carbohydrate precursors, such as glycerol, organic acids and amino acids. FBPases are members of lithium sensitive phosphatases a large superfamily which includes three families of inositol phosphatases and FBPases (phosphoesterase clan CL0171, AA sequences 3167 from Pfam data base). They are already reported as target for the treatment of non-insulin dependent diabetes and development of new drugs ([@B47]; [@B42]).

### rpsH (30S Ribosomal Protein S8)

The protein rpsH is one of the key RNA-binding protein having a central position within the small ribosomal subunit. It interacts widely with 16S rRNA and is fundamental for the correct folding of the central domain of the ribosomal rRNA. Furthermore, this protein regulates the synthesis of various other ribosomal proteins by binding to mRNA. In the two RNA molecules, it binds exactly to very similar sites. rpsH has a medium size and recently it has been discovered that rpsH play vital role as a significant primary RNA-binding protein in the 30S subunit. Mutations in S8 within the protein are shown to result in defective ribosomal assembly. The S8-binding site within 16S rRNA in *Escherichia coli*, has been investigated independently by a number of techniques including protein crosslinking, nuclease protection, hydroxyl-radical foot printing, RNA--RNA modification and chemical probing. The 30S ribosomal protein S8 is also one of the principal regulatory elements that control ribosomal protein synthesis by the translational feedback inhibition mechanism discovered by [@B48]. It regulates the expression of spc operon that encodes the 10 ribosomal proteins L5, L6, L14, L15, L18, L24, L30, S5, S8, and S14, respectively ([@B15]).

Protein--Protein Interaction Network for Proposed Targets
---------------------------------------------------------

Protein--protein interaction of target proteins with each other have been constructed showing two proteins, rplJ (VN94_02905/50S ribosomal protein L10) and rpsH (30S ribosomal protein S8) to be interacting directly based on highest confidence score 0.9. The confidence score is the approximate probability that a predicted link exists between two enzymes in the same metabolic map in the KEGG database. The evidences for this interaction are gene fusion, co-occurrence, co-expression, experimental and databases (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**).

Conclusion
==========

We performed a comprehensive *in silico* study of the druggability scores on all sequenced genomes of *C. diphtheria* resulting in a list of intra-strain highly druggable pockets of 10 ORFs non-homologous in human hosts. Previously, we have implemented a similar approach using other bioinformatics tools for the identification of putative therapeutic targets in *C. diphtheriae* that relied primarily on the modelome construction followed by filtering the obtained data for conserved targets ([@B25]). In that work, a final set of eight essential and non-host homologs targets were subjected to virtual screening using different compound libraries but lacked a detailed overview of the druggable protein pockets of the selected targets. Here, we further extrapolated our work to the druggable pocketome at species level and then at the end compared our final data set obtained in this work with the aforementioned published data. The comparison showed that any of the two approaches for putative targets identification in pathogenic microorganisms might provide an easy-to-handle protocol in future drug discovery projects. Our pipeline is expandable and can be applied to other bacterial species as well. In the future, we will work on Cytoscape plugins to allow for mapping essential druggable non-homologous genes to biological networks interactively for follow-up systems biology investigation ([@B9]). We believe that our approach has the potential to aid in designing drugs and/or vaccines, and in developing protein inhibitors as well as discovering new lead compounds.
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Protein--protein interactome for the identified common conserved targets. Ribosomal pathway protein (VN94_02915 rplJ, rpsH) was interacting with each other either directly or indirectly. The lines color indicates evidences of interactions that were predicted or experimentally validated.
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Tabulated are the 401 conserved target proteins with appropraite 3D structures that were used for further druggability etc. analyse.
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Summary of core Global Druggable (GD) targets along the 13 strains of C. diphtheriae with predicted druggability scores (137 GD targets).
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